Related Experiment Videos
Recent progress in hormonal therapy for advanced prostate cancer
Timothy J Daskivich1, William K Oh
1Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Current Opinion in Urology
|May 9, 2006
Summary
Early androgen deprivation therapy may benefit advanced prostate cancer patients with high-risk features. Newer estrogen therapies show promise for androgen-independent disease with reduced cardiovascular risks.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Hormonal therapy is central to advanced prostate cancer treatment.
- Androgen deprivation therapy (ADT) and secondary hormonal therapies are mainstays.
Purpose of the Study:
- To review evidence for hormonal therapy in prostate cancer.
- To highlight recent research developments in hormonal therapy for advanced prostate cancer.
Main Methods:
- Review of recent clinical studies and research findings.
- Analysis of data on androgen deprivation therapy and secondary hormonal agents.
Main Results:
- Early ADT may improve metastasis-free survival in high-risk patients.
- Fracture risk increases with ADT duration.
- Newer estrogen therapies (oral premarin, transdermal estradiol) show efficacy in androgen-independent prostate cancer with varying cardiovascular risks.
- Nilutamide, flutamide, and ketoconazole efficacy is further clarified.
Conclusions:
- Optimal ADT timing requires further randomized trial data.
- Early ADT may benefit high-risk prostate cancer patients.
- Novel estrogen-based therapies offer effective treatment for androgen-independent prostate cancer with improved cardiovascular safety profiles.